GT Biopharma, Inc. (GTBP)

GT Biopharma Income Statement

Financials in millions USD. Fiscal year is January - December.

Year Ending	TTM	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020	Dec 31, 2019
Selling, General & Admin	7.41	7.11	12.45	47.92	6.28	9.79
Research & Development	5.59	6.47	8.81	9.59	0.49	1.67
Other Operating Expenses	0	0	0	0	0	4.6
Operating Expenses	13	13.58	21.26	57.52	6.76	16.06
Operating Income	-13	-13.58	-21.26	-57.52	-6.76	-16.06
Interest Expense / Income	0	0.21	0.01	0.72	3	2.13
Other Expense / Income	-3.37	-6.19	-0.38	-0.22	18.53	20.46
Pretax Income	-9.64	-7.6	-20.88	-58.01	-28.3	-38.65
Net Income	-9.64	-7.6	-20.88	-58.01	-28.3	-38.65
Shares Outstanding (Basic)	1	1	1	1	0	0
Shares Outstanding (Diluted)	1	1	1	1	0	0
Shares Change	27.50%	26.87%	13.19%	542.06%	29.59%	14.50%
EPS (Basic)	-6.98	-5.64	-19.66	-61.80	-193.50	-0.30
EPS (Diluted)	-6.98	-5.64	-19.66	-61.80	-193.50	-0.30
Free Cash Flow	-10.11	-8.85	-15.22	-15.61	-7.26	-3.46
Free Cash Flow Per Share	-7.32	-6.57	-14.32	-16.63	-49.68	-30.66
EBITDA	-9.64	-7.38	-20.88	-57.3	-25.29	-36.52
Depreciation & Amortization	0	0	0	0	0	0
EBIT	-9.64	-7.38	-20.88	-57.3	-25.29	-36.52

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).